Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Genotypic and Mechanistic Characterization of Subtype-specific HIV Adaptation to Host Cellular Immunity.

Kinloch NN, Lee GQ, Carlson JM, Jin SW, Brumme CJ, Byakwaga H, Muzoora C, Bwana MB, Cobarrubias KD, Hunt PW, Martin JN, Carrington M, Bangsberg DR, Harrigan PR, Brockman MA, Brumme ZL.

J Virol. 2018 Oct 10. pii: JVI.01502-18. doi: 10.1128/JVI.01502-18. [Epub ahead of print]

PMID:
30305354
2.

Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens.

Kala S, Watson B, Zhang JG, Papp E, Guzman Lenis M, Dennehy M, Cameron DW, Harrigan PR, Serghides L.

Antiviral Res. 2018 Sep 17;159:45-54. doi: 10.1016/j.antiviral.2018.09.008. [Epub ahead of print]

PMID:
30236532
3.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5.

4.

Extensive host immune adaptation in a concentrated North American HIV epidemic.

Brumme ZL, Kinloch NN, Sanche S, Wong A, Martin E, Cobarrubias KD, Sandstrom P, Levett PN, Harrigan PR, Joy JB.

AIDS. 2018 Sep 10;32(14):1927-1938. doi: 10.1097/QAD.0000000000001912.

5.

Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors.

Zhang WW, Cheung PK, Oliviera N, Robbins MA, Harrigan PR, Shahid A.

J Infect Dis. 2018 Jul 16. doi: 10.1093/infdis/jiy428. [Epub ahead of print]

PMID:
30010985
6.

Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.

McCluskey SM, Lee GQ, Kamelian K, Kembabazi A, Musinguzi N, Bwana MB, Muzoora C, Haberer JE, Hunt PW, Martin JN, Boum Y 2nd, Bangsberg DR, Harrigan PR, Siedner MJ.

AIDS Patient Care STDS. 2018 Jul;32(7):257-264. doi: 10.1089/apc.2018.0020.

PMID:
29985647
7.

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population.

Valenzuela-Ponce H, Alva-Hernández S, Garrido-Rodríguez D, Soto-Nava M, García-Téllez T, Escamilla-Gómez T, García-Morales C, Quiroz-Morales VS, Tapia-Trejo D, Del Arenal-Sánchez S, Prado-Galbarro FJ, Hernández-Juan R, Rodríguez-Aguirre E, Murakami-Ogasawara A, Mejía-Villatoro C, Escobar-Urias IY, Pinzón-Meza R, Pascale JM, Zaldivar Y, Porras-Cortés G, Quant-Durán C, Lorenzana I, Meza RI, Palou EY, Manzanero M, Cedillos RA, Aláez C, Brockman MA, Harrigan PR, Brumme CJ, Brumme ZL, Ávila-Ríos S, Reyes-Terán G; Mesoamerican HIV Project Group.

Sci Rep. 2018 Apr 17;8(1):6111. doi: 10.1038/s41598-018-23849-7.

8.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

Penrose KJ, Brumme CJ, Scoulos-Hanson M, Hamanishi K, Gordon K, Viana RV, Wallis CL, Harrigan PR, Mellors JW, Parikh UM.

Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618762985. doi: 10.1177/2040206618762985.

9.

Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada.

Wheeler J, Chan S, Harrigan PR, Becker M, Kasper K, Keynan Y.

Int J STD AIDS. 2018 Apr;29(5):520-522. doi: 10.1177/0956462418760426. No abstract available.

PMID:
29513131
10.

Veterans and Mental Health.

Harrigan PN.

Am J Nurs. 2018 Feb;118(2):10. doi: 10.1097/01.NAJ.0000530226.63705.c3. No abstract available.

PMID:
29369854
11.

The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.

Jones BR, Howe AYM, Harrigan PR, Joy JB.

Virus Evol. 2018 Jan 16;4(1):vex041. doi: 10.1093/ve/vex041. eCollection 2018 Jan.

12.

Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.

Hashemi P, Barreto K, Bernhard W, Lomness A, Honson N, Pfeifer TA, Harrigan PR, Sadowski I.

EMBO Mol Med. 2018 Feb;10(2):160-174. doi: 10.15252/emmm.201708193.

13.

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.

Harris M, Ganase B, Watson B, Harrigan PR, Montaner JSG, Hull MW.

AIDS Res Ther. 2017 Nov 2;14(1):59. doi: 10.1186/s12981-017-0185-4.

14.

Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.

Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R.

J Infect Dis. 2017 Dec 1;216(suppl_9):S829-S833. doi: 10.1093/infdis/jix397.

PMID:
28968834
15.

A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015.

Olding M, Enns B, Panagiotoglou D, Shoveller J, Harrigan PR, Barrios R, Kerr T, Montaner JSG, Nosyk B.

J Int AIDS Soc. 2017 Sep 19;20(1):21941. doi: 10.7448/IAS.20.1.21941. Review.

16.

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.

Rocheleau G, Franco-Villalobos C, Oliveira N, Brumme ZL, Rusch M, Shoveller J, Brumme CJ, Harrigan PR.

PLoS One. 2017 Sep 22;12(9):e0184848. doi: 10.1371/journal.pone.0184848. eCollection 2017.

17.

Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches.

Lee GQ, Bangsberg DR, Mo T, Lachowski C, Brumme CJ, Zhang W, Lima VD, Boum Y 2nd, Mwebesa BB, Muzoora C, Andia I, Mbalibulha Y, Kembabazi A, Carroll R, Siedner MJ, Haberer JE, Mocello AR, Kigozi SH, Hunt PW, Martin JN, Harrigan PR.

AIDS. 2017 Nov 13;31(17):2345-2354. doi: 10.1097/QAD.0000000000001619.

PMID:
28832407
18.

Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion.

Gonzalez-Serna A, Ajaykumar A, Gadawski I, Muñoz-Fernández MA, Hayashi K, Harrigan PR, Côté HCF.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e29-e32. doi: 10.1097/QAI.0000000000001446. No abstract available.

19.

Human Immunodeficiency Virus Viral Load Rebound Near Delivery in Previously Suppressed, Combination Antiretroviral Therapy-Treated Pregnant Women.

Boucoiran I, Albert AYK, Tulloch K, Wagner EC, Pick N, van Schalkwyk J, Harrigan PR, Money D.

Obstet Gynecol. 2017 Sep;130(3):497-501. doi: 10.1097/AOG.0000000000002133.

PMID:
28796673
20.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.

Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW.

PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.

21.

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

Jacka B, Bray BC, Applegate TL, Marshall BDL, Lima VD, Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Krajden M, Montaner JSG, Grebely J Senior.

J Viral Hepat. 2018 Jan;25(1):28-36. doi: 10.1111/jvh.12758. Epub 2017 Sep 4.

PMID:
28719060
22.

Informing infant and young child feeding programming in humanitarian emergencies: An evidence map of reviews including low and middle income countries.

Prudhon C, Benelli P, Maclaine A, Harrigan P, Frize J.

Matern Child Nutr. 2018 Jan;14(1). doi: 10.1111/mcn.12457. Epub 2017 Jul 3. Review.

PMID:
28670790
23.

Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.

Rocheleau G, Brumme CJ, Shoveller J, Lima VD, Harrigan PR.

Clin Microbiol Infect. 2018 Feb;24(2):185-191. doi: 10.1016/j.cmi.2017.06.014. Epub 2017 Jun 23.

PMID:
28652115
24.

Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Lee GQ, McCluskey S, Boum Y 2nd, Hunt PW, Martin JN, Bangsberg DR, Gao X, Harrigan PR, Haberer JE, Siedner MJ.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):188-192. doi: 10.1097/QAI.0000000000001487.

25.

Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virus-Infected People Who Use Illicit Drugs in a Canadian Setting.

Socías ME, Nosova E, Kerr T, Hayashi K, Harrigan PR, Shoveller J, Montaner J, Milloy MJ.

Clin Infect Dis. 2017 Sep 1;65(5):796-802. doi: 10.1093/cid/cix428.

26.

Emergent drug resistance with integrase strand transfer inhibitor-based regimens.

Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, Lima VD, Guillemi S, Montaner JSG, Barrios R.

AIDS. 2017 Jun 19;31(10):1425-1434. doi: 10.1097/QAD.0000000000001494.

PMID:
28375875
27.

Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.

Nosyk B, Zang X, Min JE, Krebs E, Lima VD, Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JSG.

Lancet HIV. 2017 Jul;4(7):e303-e310. doi: 10.1016/S2352-3018(17)30045-0. Epub 2017 Mar 30.

28.

Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion.

Leung JM, Fishbane N, Jones M, Morin A, Xu S, Liu JC, MacIsaac J, Milloy MJ, Hayashi K, Montaner J, Horvath S, Kobor M, Sin DD, Harrigan PR, Man SF.

Aging (Albany NY). 2017 Feb 23;9(3):687-705. doi: 10.18632/aging.101184.

29.

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification.

Lima VD, Wang L, Brumme C, Wu L, Montaner JS, Harrigan PR.

PLoS One. 2017 Feb 2;12(2):e0171155. doi: 10.1371/journal.pone.0171155. eCollection 2017.

30.

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Knox DC, Anderson PL, Harrigan PR, Tan DH.

N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639. No abstract available.

31.

Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.

Balachandran A, Wong R, Stoilov P, Pan S, Blencowe B, Cheung P, Harrigan PR, Cochrane A.

Retrovirology. 2017 Jan 26;14(1):7. doi: 10.1186/s12977-017-0330-0.

32.

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O.

Antivir Ther. 2017;22(5):431-441. doi: 10.3851/IMP3123. Epub 2017 Jan 9.

PMID:
28067632
33.

Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.

Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR.

HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.

PMID:
28067119
34.

Robust Synthetic Circuits for Two-Dimensional Control of Gene Expression in Yeast.

Aranda-Díaz A, Mace K, Zuleta I, Harrigan P, El-Samad H.

ACS Synth Biol. 2017 Mar 17;6(3):545-554. doi: 10.1021/acssynbio.6b00251. Epub 2016 Dec 27.

35.

Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication.

Shkreta L, Blanchette M, Toutant J, Wilhelm E, Bell B, Story BA, Balachandran A, Cochrane A, Cheung PK, Harrigan PR, Grierson DS, Chabot B.

Nucleic Acids Res. 2017 Apr 20;45(7):4051-4067. doi: 10.1093/nar/gkw1223.

36.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Penrose KJ, Wallis CL, Brumme CJ, Hamanishi KA, Gordon KC, Viana RV, Harrigan PR, Mellors JW, Parikh UM.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01805-16. doi: 10.1128/AAC.01805-16. Print 2017 Feb.

37.

In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Rahimi A, Anmole G, Soto-Nava M, Escamilla-Gomez T, Markle T, Jin SW, Lee GQ, Harrigan PR, Bangsberg DR, Martin J, Avila-Rios S, Reyes-Teran G, Brockman MA, Brumme ZL.

J Virol Methods. 2017 Feb;240:32-41. doi: 10.1016/j.jviromet.2016.11.004. Epub 2016 Nov 16.

38.

An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition.

St-Jean M, Harrigan PR, Sereda P, Montaner J, Lima VD.

HIV Med. 2017 May;18(5):342-353. doi: 10.1111/hiv.12435. Epub 2016 Oct 4.

PMID:
27704659
39.

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.

Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Álvaro-Meca A, García-Álvarez M, Harrigan PR, Fedele CG, Briz V, Vázquez-Morón S, Resino S.

PLoS One. 2016 Sep 29;11(9):e0163197. doi: 10.1371/journal.pone.0163197. eCollection 2016.

40.

Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase.

Telwatte S, Brumme CJ, Hearps AC, Latham CF, Hayward JA, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G.

AIDS. 2016 Nov 28;30(18):2787-2793.

PMID:
27677159
41.

A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

Gonzalez-Serna A, Swenson LC, Watson B, Zhang W, Nohpal A, Auyeung K, Montaner JS, Harrigan PR.

Clin Microbiol Infect. 2016 Dec;22(12):1004.e9-1004.e16. doi: 10.1016/j.cmi.2016.08.012. Epub 2016 Aug 30.

42.
43.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

44.

Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.

Poon AF, Gustafson R, Daly P, Zerr L, Demlow SE, Wong J, Woods CK, Hogg RS, Krajden M, Moore D, Kendall P, Montaner JS, Harrigan PR.

Lancet HIV. 2016 May;3(5):e231-8. doi: 10.1016/S2352-3018(16)00046-1. Epub 2016 Apr 7.

45.

Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda.

Lee GQ, Lachowski C, Cai E, Lima VD, Boum Y, Muzoora C, Mocello AR, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR.

AIDS. 2016 Jul 17;30(11):1781-8. doi: 10.1097/QAD.0000000000001128.

46.

The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.

Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JSG, Poon AFY.

Lancet Infect Dis. 2016 Jun;16(6):698-702. doi: 10.1016/S1473-3099(16)00124-9. Epub 2016 Mar 30.

47.

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, Milloy MJ, Krajden M, Olmstead A, Joy JB, Marshall BD, Hayashi K, Pybus OG, Lima VD, Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, Grebely J.

J Hepatol. 2016 Jun;64(6):1247-55. doi: 10.1016/j.jhep.2016.02.031. Epub 2016 Feb 26.

48.

A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing.

Cheung PK, Horhant D, Bandy LE, Zamiri M, Rabea SM, Karagiosov SK, Matloobi M, McArthur S, Harrigan PR, Chabot B, Grierson DS.

J Med Chem. 2016 Mar 10;59(5):1869-79. doi: 10.1021/acs.jmedchem.5b01357. Epub 2016 Feb 29.

PMID:
26878150
49.

A Thematic Analysis of Mothers' Motivations for Blogging.

Pettigrew S, Archer C, Harrigan P.

Matern Child Health J. 2016 May;20(5):1025-31. doi: 10.1007/s10995-015-1887-7.

PMID:
26662282
50.

Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial.

Doig GS, Simpson F, Heighes PT, Bellomo R, Chesher D, Caterson ID, Reade MC, Harrigan PW; Refeeding Syndrome Trial Investigators Group.

Lancet Respir Med. 2015 Dec;3(12):943-52. doi: 10.1016/S2213-2600(15)00418-X. Epub 2015 Nov 18.

PMID:
26597128

Supplemental Content

Loading ...
Support Center